Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen

Cancer Research

Volumn 56, Issue 1, 1996, Pages 21-26

  Lin, Ken Yu ^a   Guarnieri, Frank G ^a   Staveley O'Carroll, Kevin F ^a   Levitsky, Hyam I ^a   August, J Thomas ^a   Pardoll, Drew M ^a   Wu, Tzyy Choou ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CHIMERA; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION; VACCINIA VIRUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL, TUMOR; BASE SEQUENCE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; VACCINES, SYNTHETIC;

EID: 0030068375     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254: 713-716, 1991.
2. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V , Hamada, H., Pardoll, D., and Mulligan, R C Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA, 90. 3539-3543, 1993
3. Topalian, S. L., Rivoltini, L , Mancini, M., Ng, J., Hartzman, R. J , and Rosenberg, S. A. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells Int J. Cancer, 58: 69-79, 1994.
4. Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P F., Kawakami, Y , and Rosenberg, S. A Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosine gene. Proc. Natl. Acad Sci USA, 91: 9461-9465, 1994.
5. Ostrand-Rosenberg, S., Thakur, A., and Clements, V Rejection of mouse sarcoma cells after transfection of MHC class II genes J Immunol , 144: 4068-71, 1990.
6. James, R F., Edwards, S., Hui, K. M , Bassett, P. D., and Grosveld, F The affect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36 16. Immunology, 72: 213-218, 1991.
7. Chen, P. W , and Ananthaswamy, H. N. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class n antigens or IL-2. J. Immunol , 151: 244-255, 1993.
8. Greenberg, P. D., Kern, D E , and Cheever, M A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2-T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med., 161. 1122-1134, 1985
9. Tew, J G , Kosco, M. H., Burton, G. F , and Szakal, A. K. Follicular dendritic cells as accessory cells. Immunol Rev., 117. 185-211, 1990.
10. Sprent, J T and B memory cells Cell, 76. 315-322, 1994.
11. Blum, J. S., and Cresswell, P Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc. Natl. Acad Sci USA, 85: 3975-3979, 1988.
12. Neefjes, J J., Stollorz, V., Peters, P. J., Geuze, H. J., and Ploegh, H L. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell, 61: 171-183, 1990
13. Yewdell, J W., and Bennink, J. R The binary logic of antigen processing and presentation to T cells. Cell, 62: 203-206, 1990.
14. Germain, R. N. Immunology the ins and outs of antigen processing and presentation. Nature (Lond.), 322. 687-689, 1986
15. Wu, T-C., Guarnieri, F. G , Staveley-O'Carroll, K. F., Viscidi, R. P , Levitsky, H I, Hedrick, L., Cho, K. R , August, T., and Pardoll, D. M. Engineering a novel pathway for MHC class II presentation of HPV-16 E7. Proc. Natl. Acad. Sci. USA, 92: 11671-11675, 1995.
16. Earl, P., and Moss, B. Preparation of cell cultures and vaccinia virus stocks Curr Protocols Mol. Biol , 2: 16 16 1-16.16 7, 1993.
17. Earl, P., and Moss, B. Generation of recombinant vaccinia viruses. Curr. Protocols Mol Biol., 2: 16.17.1-16.17.16, 1993.
18. Moss, B., and Earl, P. Expression of proteins in mammalian cells using vaccinia viral vectors. Curr. Protocols Mol. Biol , 2: 16.15 1-16.15.5, 1993.
19. Lewis, V., Green, S. A., Marsh, M , Vihko, P , Helenius, A., and Mellman, I. Glycoproteins of the lysosomal membrane. J. Cell Biol., 100: 1839-1847, 1985
20. Chen, J. W., Murphy, T. L., Willingham, M. C., Pastan, I., and August, J. T. Identification of two lysosomal membrane glycoproteins. J. Cell Biol., 101: 85-95, 1985.
21. Williams, M. A., and Fukuda, M. Accumulation of membrane glycoproteins in lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail. J. Cell Biol., 111: 955-966, 1990.
22. Guarnieri, F. G., Arterburn, L. M., Penno, M. B., Cha, Y., and August, J. T. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. J. Biol. Chem., 268: 1941-1946, 1993.
23. Wu, T. C Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol , 6: 746-754, 1994.
24. Halbert, C. L., Demers, G. W., and Galloway, D. A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol., 65: 473-478, 1991.
25. Seedorf, K., Krammer, G., Durst, M., Suhai, S., and Rowekamp, W. G. Human papillomavirus type 16 DNA sequence. Virology, 145: 181-185, 1985.
26. Levitsky, H. I., Lazenby, A., Hayashi, R. J., and Pardoll, D. M. In vivo priming of two distinct antitumor effector populations, the role of MHC class I expression J. Exp. Med , 179: 1215-1224, 1994.
27. Dialynas, D. P., Quan, Z. S., Wall, K. A , Pierres, A., Quintans, J., Loken, M. R , Pierres, M., and Fitch, F. W. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1 5 similarity ofL3T4 to the human Leu-3/T4 molecule. J. Immunol. 131: 2445-2451, 1983.
28. Sarmiento, M., Glasebrook, A. L., and Fitch, F. W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement J. Immunol., 125: 2665-2672, 1980.
29. Koo, G. C., Dumont, F. J., Tutt, M., Hackett, J , Jr , and Kumar, V. The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J. Immunol., 137 3742-3747, 1986.
30. Crook, T., Morgenstern, J. P., Crawford, L , and Banks, L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J., 8: 513-519, 1989.
31. Meneguzzi, G., Cerni, C., Kieny, M. P., and Lathe, R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology, 181. 62-69, 1991